A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared with Venetoclax Plus Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia
Study Number: BGB-11417-301
Study Summary:
The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL)
Status: Open
Open in Bloomington, Galesburg, Ottawa, Pekin, Peoria, Peru, and Washington
Study Coordinator(s)
- Navigator Heather, 309-243-3661 hthulean@illinoiscancercare.com
- Hannah, 309-243-3628 hknight@illinoiscancercare.com
